Restless Legs Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Restless Legs Syndrome - Pipeline Review, H2 2016

Restless Legs Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Restless Legs Syndrome - Pipeline Review, H2 2016
Published Jul 20, 2016
44 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Restless Legs Syndrome - Pipeline Review, H2 2016, provides an overview of the Restless Legs Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
- The report reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Restless Legs Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Restless Legs Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Restless Legs Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Restless

  
Source:
Document ID
GMDHC8248IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Restless Legs Syndrome Overview61
Therapeutics Development71
  Pipeline Products for Restless Legs Syndrome Overview71
Restless Legs Syndrome Therapeutics under Development by Companies81
Restless Legs Syndrome Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Restless Legs Syndrome Products under Development by Companies121
Restless Legs Syndrome Companies Involved in Therapeutics Development136
  Alexza Pharmaceuticals, Inc.131
  Galenica Ltd.141
  Hisamitsu Pharmaceutical Co., Inc.151
  Ligand Pharmaceuticals, Inc.161
  Mundipharma International Ltd171
  Omeros Corporation181
Restless Legs Syndrome Therapeutics Assessment199
  Assessment by Monotherapy Products191
  Assessment by Combination Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type271
Drug Profiles289
  (naloxone hydrochloride + oxycodone hydrochloride) ER Drug Profile282
  aplindore fumarate Drug Profile301
  AZ-008 Drug Profile311
  ferric carboxymaltose Drug Profile322
  OMS-527 Drug Profile342
  ropinirole hydrochloride Drug Profile361
Restless Legs Syndrome Dormant Projects371
Restless Legs Syndrome Discontinued Products381
Restless Legs Syndrome Product Development Milestones394
  Featured News &Press Releases391
    May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs391
    Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome401
    Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome411
    Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome411
    Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease421
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Restless Legs Syndrome - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Restless-Legs-Syndrome-Pipeline-Review-H2-2016-2088-16222>
  
APA:
Global Markets Direct - Market Research. (2016). Restless Legs Syndrome - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Restless-Legs-Syndrome-Pipeline-Review-H2-2016-2088-16222>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.